How much does entrectinib cost?

Entrectinib is a targeted therapy drug used to treat certain types of cancer, including NTRK gene fusion-positive tumors and ROS1-positive non-small cell lung cancer. The drug belongs to a class of drugs called tyrosine kinase inhibitors, which inhibit the proliferation and spread of tumors by interfering with their growth signaling pathways.

Entrectinib has been launched in China and has been included in medical insurance. Patients can buy it domestically, but the price is very high, about more than 20,000 yuan. For specific prices and medical insurance reimbursement, please consult the local hospital pharmacy. The cheaper ones abroad are entrectinib generics, mainly Laos generics. The price is about one to two thousand yuan, and the ingredients of the original drug and the generic are basically the same.

NTRKgene fusion is a rare but important cancer molecular mutation that causes theNTRK gene to fuse with other genes to form a new fusion protein. This fusion protein can promote the growth and survival of tumor cells and therefore becomes a therapeutic target. Entrectinib can specifically inhibit the activity of NTRK fusion protein, thereby blocking the proliferation and growth of tumor cells.

In addition,ROS1 is a receptor tyrosine kinase that plays an important role in various cancers such as non-small cell lung cancer. ROS1Tumors that are positive often have specific ROS1 gene mutations or fusions, which lead to overactivation of this receptor and promote tumor development. Entrectinib blocks this signaling pathway by inhibiting the activity of ROS1 protein, thereby inhibiting the growth and spread of tumor cells.

Entrectinib is usually administered in the form of oral capsules, which can be taken regularly by patients as recommended by their doctor. In clinical trials, entrectinib has shown significant efficacy in patients with NTRK gene fusion-positive tumors and ROS1-positive non-small cell lung cancer. Some studies have shown that entrectinib can be used as a first-line treatment for these patients and as a subsequent treatment option when other treatments have failed or are intolerable.